What Is Ligand Pharmaceuticals Incorpor (LGND) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Ligand Pharmaceuticals Incorpor's intrinsic value is estimated at $104.57, suggesting the stock is overvalued at its current price of $309.25. With 13 out of 13 models flagging downside (-66.2% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: PWERM targets $273.45 (-11.6%), versus Dynamic NAV at $16.31 (-94.7%). This +83.1% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About LGND?
13 of 13 models are currently active for LGND. All 13 active models suggest the stock trades above fair value. The Bayesian DCF estimates LGND's intrinsic value at $68.75, implying -77.8% downside from the current price. See which stocks rank higher →
How Does LGND Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, LGND ranks #25 by Quality of Company score. CirclFi's QOC score of 8.4/10 evaluates 32 fundamental signals. A score of 8.4 places LGND in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Ligand Pharmaceuticals Incorpor competes in an environment where patent cliff exposure often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is LGND a Value Trap?
CirclFi's Value Trap algorithm assigns LGND a score of 20/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Ligand Pharmaceuticals Incorpor. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Ligand Pharmaceuticals Incorpor is rated at 8.4/10. This strong-tier score demonstrates strong fundamentals across the majority of our quality signals.
The gap between the most bullish and bearish model spans +83.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every LGND valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across LGND's 13 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad